Revolution Medicines, Inc. (NASDAQ:RVMD) experienced a significant pre-market surge of 16.21% following the release of landmark clinical trial data for its lead drug candidate.

The sharp increase was driven by detailed results from the global Phase 3 RASolute 302 clinical trial presented at the ASCO annual meeting, which evaluated daraxonrasib for metastatic pancreatic ductal adenocarcinoma. The data showed that daraxonrasib more than doubled median overall survival to 13.2 months compared to 6.7 months for standard chemotherapy, while also reducing the risk of death by 60%.

These breakthrough results represent a potential paradigm shift in pancreatic cancer treatment, where RAS mutations are highly prevalent but targeted therapies have been scarce. The positive data has generated substantial market optimism, with analysts responding by reiterating Buy ratings and raising price targets based on the strong pivotal results and launch prospects for daraxonrasib.